Luseogliflozin (hydrate)

Luseogliflozin (hydrate) 화학적 특성, 용도, 생산

• 개요

  Luseogliflozin hydrate, which is an SGLT2 inhibitor approved in Japan in March 2014 for the treatment of type 2 diabetes, was discovered by Taisho Pharmaceutical and jointly developed and marketed with Novartis as Lusefi®. Luseogliflozin selectively binds and inhibits human SGLT2 with a Ki of 1.10 nM and IC50 value of 2.26 nM.

Luseogliflozin (hydrate) 공급 업체

Global(4)Suppliers